2-fluoro-4-(2'-hydroxymethylphenyl)aniline | 228259-65-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-fluoro-4-(2'-hydroxymethylphenyl)aniline
• 英文别名: [2-(4-amino-3-fluorophenyl)phenyl]methanol
• CAS: 228259-65-2
• 化学式: C₁₃H₁₂FNO
• 分子量: 217.243
• InChiKey: HDQHAONORYDAMI-UHFFFAOYSA-N

物化性质

• 沸点：
  388.9±37.0 °C(Predicted)
• 密度：
  1.241±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  46.2
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-fluoro-4-(2'-hydroxymethylphenyl)aniline 在 咪唑 、 盐酸 、 四溴化碳 、 乙酰氧肟酸 、 potassium carbonate 、 三乙胺 、 三苯基膦 作用下， 以 乙醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 生成 1-(3'-aminobenzisoxazol-5'-yl)-3-trifluoromethyl-5-[(2'-bromomethyl-3-fluoro-[1,1']-biphen-4-yl)aminocarbonyl]pyrazole
  参考文献：
  名称：

  Aminobenzisoxazoles with biaryl P4 moieties as potent, selective, and orally bioavailable factor Xa inhibitors

  摘要：

  We have previously reported on a series of aminobenzisoxazoles as potent, selective, and orally bioavailable factor Xa inhibitors. which culminated in the discovery of razaxaban. Herein, we describe another approach to improve factor Xa inhibitory potency and pharmacokinetic profile by incorporating basic and water soluble functionalities on the terminal ring of the P4 biaryl group found ill our earlier Xa inhibitors. This approach resulted in a series of potent, selective, and orally bioavailable factor Xa inhibitors. (C) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.01.010
• 作为产物：
  描述：

  4(2'-formylphenyl)-2-fluoroaniline 在 sodium tetrahydroborate 作用下， 以95%的产率得到2-fluoro-4-(2'-hydroxymethylphenyl)aniline
  参考文献：
  名称：

  Aminobenzisoxazoles with biaryl P4 moieties as potent, selective, and orally bioavailable factor Xa inhibitors

  摘要：

  We have previously reported on a series of aminobenzisoxazoles as potent, selective, and orally bioavailable factor Xa inhibitors. which culminated in the discovery of razaxaban. Herein, we describe another approach to improve factor Xa inhibitory potency and pharmacokinetic profile by incorporating basic and water soluble functionalities on the terminal ring of the P4 biaryl group found ill our earlier Xa inhibitors. This approach resulted in a series of potent, selective, and orally bioavailable factor Xa inhibitors. (C) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.01.010

文献信息

• Nitrogen containing heteromatics with ortho-substituted P1s as factor Xa inhabitors
  申请人：DuPont Pharmaceuticals Company

  公开号：US06271237B1

  公开（公告）日：2001-08-07

  The present application describes nitrogen containing heteroaromatics with ortho-substituted P1's and derivatives thereof of formula I: or pharmaceutically acceptable salt or prodrug forms thereof, wherein J is N or NH and D is substituted ortho to G on E and may be CH2NH2, which are useful as inhibitors of factor Xa.

  本申请描述了含有氮的杂芳环化合物，其中P1位被邻位取代，以及它们的衍生物，其公式为I：或其药用可接受的盐或前药形式，其中J是N或NH，D在E上的G的邻位被取代，可以是CH2NH2，它们作为因子Xa抑制剂是有用的。
• Nitrogen containing heteroaromatics with ortho-substituted P1's as factor Xa inhibitors
  申请人：——

  公开号：US20020016326A1

  公开（公告）日：2002-02-07

  The present application describes nitrogen containing heteroaromatics with ortho-substituted P1's and derivatives thereof of formula I: 1 or pharmaceutically acceptable salt or prodrug forms thereof, wherein J is N or NH and D is substituted ortho to G on E and may be CH 2 NH 2 , which are useful as inhibitors of factor Xa.

  本申请描述了具有正交取代P1的含氮杂环化合物及其衍生物的公式I：1或其药学上可接受的盐或前药形式，其中J为N或NH，D被取代在E上的G的正交位置，可以是CH2NH2，它们可用作因子Xa的抑制剂。
• US6271237B1
  申请人：——

  公开号：US6271237B1

  公开（公告）日：2001-08-07
• US6548525B2
  申请人：——

  公开号：US6548525B2

  公开（公告）日：2003-04-15
• Aminobenzisoxazoles with biaryl P4 moieties as potent, selective, and orally bioavailable factor Xa inhibitors
  作者：Mimi L. Quan、Qi Han、John M. Fevig、Patrick Y.S. Lam、Steve Bai、Robert M. Knabb、Joseph M. Luettgen、Pancras C. Wong、Ruth R. Wexler

  DOI：10.1016/j.bmcl.2006.01.010

  日期：2006.4

  We have previously reported on a series of aminobenzisoxazoles as potent, selective, and orally bioavailable factor Xa inhibitors. which culminated in the discovery of razaxaban. Herein, we describe another approach to improve factor Xa inhibitory potency and pharmacokinetic profile by incorporating basic and water soluble functionalities on the terminal ring of the P4 biaryl group found ill our earlier Xa inhibitors. This approach resulted in a series of potent, selective, and orally bioavailable factor Xa inhibitors. (C) 2006 Elsevier Ltd. All rights reserved.